The Value of a Novel Panel of Cervical Cancer Biomarkers for Triage of HPV Positive Patients and for Detecting Disease Progression

Pathology & Oncology Research

Cara M. Martin²  Márta Benczik⁵  Adrienn Géresi⁵  Csaba Jeney⁴  Schaff Zsuzsanna⁴  Miklos Nyíri⁵  Laura Kovács⁵  Róbert Koiss¹  Adrienn Kocsis⁵  Gábor Sobel⁴  Loretto Pilkington²  Christine White²  Lynne Kelly²  Norbert Varga⁵  Johanna Mózes⁵  Edit Babarczi¹  Sebe Attila⁴  Borbála Kaltenecker³  Helen Keegan²  John O’Leary² 

[1] United Hospital of St. Stephan and Laszlo$$;Trinity College Dublin$$Coombe Women and Infants University Hospital$$;Genoid Ltd$$;Semmelweis University$$;CellCall Ltd$$

关键词: Cellular biomarker;    biomarker;    cervical cancer;    carcinogenesis;   

DOI  :  10.1007/s12253-016-0094-1

学科分类：生理学与病理学

来源: Springer

【 摘 要 】

In the era of primary vaccination against HPV and at the beginning of the low prevalence of cervical lesions, introduction of screening methods that can distinguish between low- and high-grade lesions is necessary in order to maintain the positive predictive value of screening. This case-control study included 562 women who attended cervical screening or were referred for colposcopy and 140 disease free controls, confirmed by histology and/or cytology. The cases were stratified by age. Using routine exfoliated liquid based cytological samples RT-PCR measurements of biomarker genes, high-risk HPV testing and liquid based cytology were performed and used to evaluate different testing protocols including sets of genes/tests with different test cut-offs for the diagnostic panels. Three new panels of cellular biomarkers for improved triage of hrHPV positive women (diagnostic panel) and for prognostic assessment of CIN lesions were proposed. The diagnostic panel (PIK3AP1, TP63 and DSG3) has the potential to distinguish cytologically normal hrHPV+ women from hrHPV+ women with CIN2+. The prognostic gene panels (KRT78, MUC5AC, BPIFB1 and CXCL13, TP63, DSG3) have the ability to differentiate hrHPV+ CIN1 and carcinoma cases. The diagnostic triage panel showed good likelihood ratios for all age groups. The panel showed age-unrelated performance and even better diagnostic value under age 30, a unique feature among the established cervical triage tests. The prognostic gene-panels demonstrated good discriminatory power and oncogenic, anti-oncogenic grouping of genes. The study highlights the potential for the gene expression panels to be used for diagnostic triage and lesion prognostics in cervical cancer screening.

【 授权许可】

Unknown